Skip to content

Halozyme Therapeutics

US · HALO #1276 by market cap Listed 1970
91.35 -1.69 -1.82%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Recent news

  • Rating change
    Wells Fargo Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $75
    Market Newswire · 2026/6/15
  • Rating change
    H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/10/13
  • Company notice
    Halo Xin.com: Prompt Announcement on Disclosing the Report for the Third Quarter of 2023
    SZSI · 2023/10/24
  • Rating change
    H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $115
    Market Newswire · 2026/10/7
  • Rating change
    Analysts' Top NA Picks: High Roller Technologies, Inc. (ROLR), Halozyme (HALO)
    TipRanks · 2026/9/3
  • Rating change
    H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $95
    Market Newswire · 2026/7/22
  • Company notice
    Halo Technologies Holdings Ltd: HALO to issue Convertible Notes to raise up to AUD6.75m
    N/A · 2024/8/29
  • Rating change
    Leerink Partners Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $110
    Market Newswire · 2026/10/8
  • Morgan Stanley Downgrades Halozyme Therapeutics(HALO.US) to Hold Rating, Raises Target Price to $109
    Market Newswire · 2026/11/11
  • Citizens JMP Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $149
    Market Newswire · 2026/11/6
  • Company notice
    Better Choice Co | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-HEP Partners LLC(7.5%),HH-Halo GP LLC(7.5%), etc.
    SEC · 2024/2/15
  • Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Hold Rating, Maintains Target Price $109
    Market Newswire · 2026/11/17
  • Rating change
    TD Cowen Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Raises Target Price to $130
    Market Newswire · 2026/10/13
  • Company notice
    Akanda | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Halo Collective Inc.(0%)
    SEC · 2024/2/21
  • Halozyme Therapeutics(HALO.US) Officer Sells US$6 Million in Common Stock
    Market Newswire · 2026/11/17
  • Company notice
    RIMBACO: JOINT ANNOUNCEMENT1. CLOSE OF MANDATORY UNCONDITIONAL CASH OFFER BY CMB INTERNATIONAL CAPITAL LIMITED AND CEB INTERNATIONAL CAPITAL CORPORATION LIMITED FOR AND ON BEHALF OF AUREOLE HALO LIMITED TO ACQUIRE ALL THE ISSUED SHARES OF RIMBACO GROUP GLOBAL LIMIT
    HKEX · 2026/7/7
  • H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/11/20
  • Rating change
    Goldman Sachs Maintains Halozyme Therapeutics(HALO.US) With Sell Rating, Raises Target Price to $57
    Market Newswire · 2026/6/15
  • Rating change
    A Quick Look at Today's Ratings for Halozyme Therapeutics(HALO.US), With a Forecast Between $93 to $115
    Market Newswire · 2026/8/8
  • Rating change
    Morgan Stanley Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $93
    Market Newswire · 2026/6/15
  • Rating change
    J.P. Morgan Sticks to Its Hold Rating for Halozyme (HALO)
    TipRanks · 2026/5/20
  • GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Revenue Range $1.86B - $1.93B, Vs. FactSet Est of $1.88B
    MT Newswires · 2026/11/6
  • GUIDANCE: (HALO) Halozyme Therapeutics Now Expects 2026 Adjusted EPS Range $8.75 - $9.05, Vs. FactSet Est of $8.62
    MT Newswires · 2026/11/6
  • H.C. Wainwright Maintains Halozyme Therapeutics(HALO.US) With Buy Rating, Maintains Target Price $130
    Market Newswire · 2026/11/6
  • Tesla's Roadster and the SpaceX Halo -- Barrons.com
    Barron's · 2026/10/19

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:02:40 · For reference only, not investment advice and not tailored to your situation.

Halozyme Therapeutics discussion 0 comments

Add a comment